If you manage a wound care program whether it’s in a physician office, a hospital outpatient department, or a therapy-based clinic the changes that took effect on January 1, 2026 aren’t something you can keep putting off. They’re already in place, they’re major, and they directly impact how much you’re paid, which billing codes you can use, and how closely CMS may scrutinize your claims.
This guide walks you through every major change in plain language. Not jargon. Not hedged policy-speak. Just a clear explanation of what happened, why CMS did it, and what you need to do about it right now.
To understand the 2026 rules, you need to understand the problem they were designed to solve. This is not a routine annual update. It is a direct response to one of the fastest-growing fraud and overspending problems Medicare has ever encountered in a single product category.
Here is the number that stopped CMS in its tracks: In 2019, Medicare’s Part B spending on skin substitute products was approximately $252 million. By 2024, that same spending line had ballooned to over $10 billion. That is a nearly 40-fold increase in five years. Spending went up 40x. The math simply does not work without manipulation.
CMS and the OIG identified exactly how the manipulation happened. Manufacturers were launching skin substitute products at artificially inflated prices because Medicare reimbursed based on Average Sales Price, a methodology designed for drugs, not wound care supplies. Higher launch price meant higher Medicare reimbursement. That created a race to the top on pricing that had nothing to do with clinical value.
The OIG found billing by clinicians in specialties unrelated to wound care. It also found claims for patients with no documented wounds. It found multiple claims submitted on the same date. This may have helped them avoid automated denial thresholds. In the most extreme case, a couple in Arizona pleaded guilty. They orchestrated a $1.2 billion fraud scheme. The scheme involved medically unnecessary wound grafts. In 2025 alone, CMS’s Fraud Defense Operations Center stopped nearly $185 million in improper payments.
That is the backstory of 2026 updates. Now you understand why the 2026 changes are so extensive. CMS did not adjust any rate. It restructured the entire payment architecture.
Most affected (q non-BLA) skin substitute products are no longer paid using drug-style ASP methodology.
Before 2026, most skin substitutes were classified as “biologicals” under Medicare and reimbursed using a drug-pricing formula called ASP+6%, average sales price plus 6 percent, for the products affected (non-BLA skin substitutes). This is the same methodology used for chemotherapy agents. It made skin substitutes extraordinarily lucrative because the payment floated with whatever price the manufacturer chose to set.
Outsource our RPM billing services to align with Medicare’s RPM codes, ensuring accurate documentation and faster payment cycles.
Effective January 1, 2026, the CMS CY 2026 Physician Fee Schedule Final Rule reclassifies most skin substitute products as “incident-to supplies.” In Medicare’s language, incident-to supplies are materials that are part of performing a clinical procedure, think sutures, gauze, or irrigating solution. They are not separately priced at a premium. They are paid as part of the care.
And with that reclassification comes a flat national payment rate. CMS finalized a single payment of “approximately” $127.28 under PFS (non-facility) and $127.14 under OPPS (facility) for CY 2026. This rate applies in both the physician office setting and the hospital outpatient department. It does not matter what the product cost your practice to purchase. Every approved product is paid at the same rate.
CMS estimates this change will reduce Medicare’s gross spending on skin substitute services by approximately $19.6 billion in 2026 alone, roughly a 90 percent reduction compared to prior spending levels. That scale tells you just how distorted the old pricing had become.
Let our software help streamline your workflow, reduce manual errors, improve claim acceptance rates, and ensure faster reimbursement.
The new system does not treat all skin substitutes as interchangeable. CMS grouped them into three categories based on how the FDA regulated them. This matters for billing because each category maps to a different payment code in the hospital outpatient setting, and CMS has announced it will set different payment rates for each category starting in 2027.
| FDA Category | What It Means |
|---|---|
| APC 6000 PMA Products | Products with full FDA Premarket Approval. These required clinical trials to prove safety and effectiveness. Highest regulatory bar. Typically class III devices with a direct treatment intent beyond wound coverage. |
| APC 6001 510(k) Products | Products cleared through FDA's 510(k) or De Novo pathway. Includes class I and II devices. Tend to be wound dressings designed to protect and maintain moisture. Moderate regulatory pathway. |
| APC 6002 361 HCT/P Products | Human cell, tissue, or cellular/tissue-based products regulated under Section 361 of the Public Health Service Act. Self-registered with FDA. No clinical trials required before marketing. Includes many amniotic membrane and allograft products. |
For 2026, all three categories are paid at the same $127.28/cm² rate. CMS deliberately chose a single rate for the first year to allow the market to stabilize before setting differentiated rates. Starting in 2027, each category will have its own rate, likely reflecting differences in evidence quality and regulatory scrutiny.
The overall OPPS payment rates increased by 2.6 percent for 2026 (based on a 3.3 percent hospital market basket increase minus a 0.7 percent productivity adjustment). This applies to standard wound care APCs, debridement, E/M visits, NPWT, and others, that are unaffected by the skin substitute changes. Total estimated OPPS payments for 2026 are approximately $101 billion.
The OPPS outlier threshold, the point at which Medicare pays extra for unusually resource-intensive cases, dropped from $8,000 in 2025 to $6,225 in 2026. Outlier payments continue at 50 percent of the amount by which a hospital’s cost exceeds 1.75 times the APC payment. The lower threshold means slightly more complex wound care cases may qualify for additional outlier payment.
Despite all the payment restructuring, CMS did not create any new CPT application codes. Codes 15271 through 15278 remain the correct codes for skin substitute application procedures in all settings. What changed is the product payment alongside those codes, not the procedure codes themselves.
CMS has now made permanent the rule that allows providers use virtual direct supervision (through real-time audio and video) for certain incident-to services. For wound care practices managing clinical staff across multiple sites, this can make supervision a lot more flexible. Just keep in mind that supervision has to be available in real time, audio-only will not count, and the rule does not apply to procedures with 10 or 90 day global periods.
The 2026 updates are not meant to penalize high-quality wound care. They are basically designed to crack down on misuse of wound care billing. Clinicians who will clearly document medical necessity, use the products correctly, and monitor utilization precisely will benefit from this update.
Please provide the following information, so our team can connect with you within 12 hours.
Or call us as 800-640-6409
